Mercy Gynecologic Oncologist, Dr. Beman Khulpateea, Discusses Research Connecting HPV Vaccine to Reduction in Cervical Cancer
A new study shows the HPV vaccine is curbing cervical cancer risk.
Published in the New England Journal of Medicine, the study found there is a significant decrease in cervical cancer patients who have received the HPV vaccine compared to those who did not.
The vaccine was developed in 2006. According to Fellowship-trained Mercy gynecologic oncologist Dr. Beman Khulpateea said the study finally puts together years of data.
"One of the things the study pointed out was the benefit of early vaccination, so people who get a vaccine at an early age -- both girls and boys -- have a lower risk of developing subsequent disease," Dr. Khulpateea said.
In the United States, doctors recommend starting HPV vaccinations at 11 or 12 years old.
Dr. Khulpateea sees patients at The Gynecologic Oncology Center at Mercy, one of Baltimore's leading centers in GYN cancers. He provides diagnosis and treatment for gynecologic disease including ovarian, uterine, cervical and vulvar cancers.
Founded in 1874 in downtown Baltimore by the Sisters of Mercy, Mercy Medical Center is a 183-licensed bed acute care university-affiliated teaching hospital. Mercy has been recognized as a top Maryland hospital by U.S. News & World Report; a Top 100 hospital for Women’s Health & Orthopedics by Healthgrades; is currently A-rated for Hospital Safety (Leapfrog Group), and is recognized by the American Nurses Credentialing Center as a Magnet Hospital. Mercy Medical Center is part of Mercy Health Services (MHS), the parent of Mercy’s primary care and specialty care physician enterprise, known as Mercy Personal Physicians, which employs more than 200 providers with locations in Baltimore, Lutherville, Overlea, Glen Burnie, Columbia and Reisterstown. For more information about Mercy, visit www.mdmercy.com, MDMercyMedia on Facebook, Twitter, or call 1-800-MD-Mercy.